Identification of blood lipid markers of docetaxel treatment in prostate cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Identification of blood lipid markers of docetaxel treatment in prostate cancer patients ; volume:14 ; number:1 ; day:27 ; month:9 ; year:2024 ; pages:1-19 ; date:12.2024
Scientific reports ; 14, Heft 1 (27.9.2024), 1-19, 12.2024
- Creator
-
Finnerty, Morgan C.
Leach, Franklin E.
Zakharia, Yousef
Nepple, Kenneth G.
Bartlett, Michael G.
Henry, Michael D.
Cummings, Brian S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-73074-8
- URN
-
urn:nbn:de:101:1-2412132119299.228908703142
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Finnerty, Morgan C.
- Leach, Franklin E.
- Zakharia, Yousef
- Nepple, Kenneth G.
- Bartlett, Michael G.
- Henry, Michael D.
- Cummings, Brian S.
- SpringerLink (Online service)
Other Objects (12)
Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
Identification of plasma lipid species as promising diagnostic markers for prostate cancer
Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
Peritumoral Delivery of Docetaxel‐TIPS Microparticles for Prostate Cancer Adjuvant Therapy
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers
Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
Identification of plasma lipid species as promising diagnostic markers for prostate cancer
Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
Peritumoral Delivery of Docetaxel‐TIPS Microparticles for Prostate Cancer Adjuvant Therapy
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers
Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
Identification of plasma lipid species as promising diagnostic markers for prostate cancer
Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
Peritumoral Delivery of Docetaxel‐TIPS Microparticles for Prostate Cancer Adjuvant Therapy
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers
Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer